Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets for Oral Suspension (US RLD: ExjadeTM Tablets for Oral Suspension) in the strengths of 125 mg, 250 mg and 500 mg.
Deferasirox binds to iron and removes it from the bloodstream.
It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)